drug
pretomanid
Marketedupdated 3mo agoby Mylan Specialty LP
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying pretomanid
- phase2Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis
- phase2Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis
- phase2PanACEA - STEP2C -01
- phase2Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
- phase3A Pan-TB Regimen Targeting Host and Microbe
- phase2Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
- phase3Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 14, 2029
~3.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
FDA exclusivities (3)
- Aug 14, 2029GAINGAIN Antibiotic (5y)3.0y
- Aug 14, 2026ODE-253Orphan Drug (7y)
- Aug 14, 2024NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that